All stories by Sohini Das
Serum applies for EU Covishield nod through AstraZeneca
Rediff.com30 Jun 2021We have applied for marketing authorisation to the EMA through AstraZeneca. We will not sell the vaccine in the EU, said a company source.
India's children may get 2 Covid vaccines by December
Rediff.com28 Jun 2021While Bharat Biotech's Covaxin is in trials among children already, Serum Institute of India will begin Novavax vaccine trials on children from July, whereas the Pfizer vaccine has been approved for adolescents in the United States; and Cadila Healthcare's ZyCoV-D has done trials on 12 year-olds and above already, reports Sohini Das.
Covid: What is Delta, Delta Plus & can vaccines fight it?
Rediff.com24 Jun 2021While virologists say theoretically the vaccine that works on Delta should work on the Delta Plus variant as well, more research is needed.
Novavax set for India launch with Serum Institute as partner
Rediff.com15 Jun 2021The Covid-19 vaccine demonstrated an overall 90.4 per cent efficacy in phase 3 clinical trials, reports Sohini Das
India could get 4th Covid vaccine as Zydus Cadila set to seek nod for ZyCoV-D
Rediff.com14 Jun 2021This could also be India's first vaccine for children aged 12 years and above as the company has conducted trials on the age group. The decision, however, lies with the regulator, reports Sohini Das
Study comparing Covishield, Covaxin has limitations: Bharat Biotech
Rediff.com9 Jun 2021Raches Ella, project lead, Covid-19 vaccines at Bharat Biotech said in a series of tweets that he was 'surprised' that media and researchers were drawing conclusions based on non-peer reviewed work.
COVID-19 Vaccine: 4 months from lab to jab
Rediff.com8 Jun 2021'Almost 70 per cent production time of a vaccine is dedicated to quality control, which is done through several hundred tests.'
Biological E inks deal with Canadian firm for mRNA Covid vaccine
Rediff.com2 Jun 2021Providence will sell up to 30 mn doses of its mRNA vaccine to Biological E. It would also provide the necessary technology transfer to make the vaccine in India, with a minimum production capacity of 600 mn doses in 2022 and targets capacity of 1 bn doses, reports Sohini Das.
Bharat Biotech to make 900 million Covaxin vaccines
Rediff.com1 Jun 2021500 million doses per annum from its two sites in Hyderabad and 200 million doses each from its Ankleshwar and Kolar facilities.
DRDO's Covid drug: Benefits. Concerns
Rediff.com31 May 2021Commercial launch and supply to major government and private hospitals is expected in mid-June.
Self-use Covid-19 testing kits to be available at stores for Rs 250
Rediff.com21 May 2021Pune's Mylab Discovery Solutions' CoviSelf, which gives results in 15 minutes, gets ICMR nod
Cipla ready to partner in Covid vaccine distribution
Rediff.com17 May 2021However, Cipla was very clear it does not want to get into vaccine manufacturing.
Covaxin output scaled up to 500 million jabs a year: Bharat Biotech
Rediff.com17 May 2021This apart, to further increase capacities, Bharat Biotech has partnered with Indian Immunologicals (IIL) to manufacture the drug substance for Covaxin. The technology transfer process is underway and IIL has the 'capabilities and expertise' to manufacture the inactivated viral vaccines at commercial scale.
Govt hopeful of vaccinating adult population by December
Rediff.com15 May 2021India expects 2.16 billion doses of Covid-19 vaccines between August and December, including the jabs that are currently in clinical trials, reports Sohini Das
Private hospitals may import Covid vaccines
Rediff.com15 May 2021Apollo Hospitals and Fortis Healthcare are open to importing vaccines.
Prices of key Covid bulk drugs shoot up as demand rises
Rediff.com12 May 2021The API of Paracetamol, a fever and pain medication, has grown 25 per cent from Rs 450-480 per kg in December 2020 to Rs 580-600 per kg in April. When compared to the pre-Covid prices of December 2019, the surge is much steeper -- around 140 per cent, reports Sohini Das.
With Covid surge, FabiFlu becomes most sold drug in India
Rediff.com11 May 2021Drugs that are used to treat Covid or used by people as immunity boosters have seen a jump in sales and, in turn, rankings.
'No preparedness planning, no accountability, no action plan'
Rediff.com8 May 2021'This government did not have any plan for safety stocks of essential medicines.'
Pharma industry posts 51.5% growth in April sales
Rediff.com8 May 2021When compared to the domestic sales of April 2019, the growth is around 37 per cent. However, compared to the previous month (March), the growth is 18.4 per cent.
Remdesivir black-market thrives as Covid cases rise
Rediff.com6 May 2021Artificial shortages and brazen hawking of the drug on the streets at 15 times the normal price rule the day as the official machinery tries desperately to stamp out the parallel market, reports Sohini Das